Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review

Overview of attention for article published in Frontiers in immunology, August 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 13 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 7 publications that cite this research output.

7

The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.

A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)

Article in Frontiers in Oncology (September 2024)

Development and application of a population pharmacokinetic model repository for caffeine dose tailoring in preterm infants

Article in Expert Opinion on Drug Metabolism & Toxicology (August 2024)

Population Pharmacokinetics and Exposure‐Response Relationship of Zimberelimab in Chinese Patients with Advanced Tumors

Article in Clinical Pharmacology in Drug Development (July 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.